{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-028595","form_type":"8-K","ticker":"PRLD","cik":"0001678660","company_name":"Prelude Therapeutics Inc","filed_at":"2022-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.627754+00:00","generated_at":"2026-06-24T02:07:18.308675+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Prelude Therapeutics Q2 2022 net loss $27.4M; cash $246.3M; IND accepted for CDK4/6 inhibitor PRT3645","bullets":["Net loss $27.4M ($0.58/share) vs $26.9M ($0.58/share) Q2 2021; R&D declined $1.1M to $21.3M.","Cash, equivalents, and marketable securities $246.3M as of June 30, 2022; funds operations into H2 2024.","FDA accepted IND for brain-penetrant CDK4/6 inhibitor PRT3645; Phase 1 to begin Q4 2022 in multiple cancers.","PRMT5 (PRT811) expansion cohort data readout and next steps expected H2 2022; MCL1 combo data by end of 2022.","SMARCA2/BRM degrader program on track to file IND by year-end 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-028595","json":"https://secwatch.observer/filing/0001564590-22-028595.json","markdown":"https://secwatch.observer/filing/0001564590-22-028595.md","text":"https://secwatch.observer/filing/0001564590-22-028595.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1678660/000156459022028595/0001564590-22-028595-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1678660/000156459022028595/prld-8k_20220809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:07:18.308675+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}